The BRAF (V600E) mutation analysis is predictive for anti-EGFR therapies (i.e., cetuximab and panitumumab). BRAF mutations account for approximately 12-15% of colorectal cancer patients.
Keywords : PI3K, EML4-ALK, BRAF, KRAS, EGFR, Pulmotype, KRAS Mutation, BRAF Mutation .